The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19

Bibliography

• Sangkuhl K, Shuldiner AR, Klein TE, et al. Platelet aggregation pathway. Pharmacogenet Genomics 2011;21(8):516-21
   PubMed Web of Science ®Google Scholar
• Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102(2):248-57
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49(24):2312-17
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261-73
   PubMed Web of Science ®Google Scholar
• Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009;52(2):141-52
   PubMed Web of Science ®Google Scholar
• Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6):1309-11
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24(11):1980-7
   PubMed Web of Science ®Google Scholar
• Mansour K, Taher AT, Musallam KM, et al. Aspirin resistance. Adv Hematol 2009;2009:937352
   PubMedGoogle Scholar
• Faraday N, Becker DM, Becker LC. Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 2007;8(10):1413-25
   PubMed Web of Science ®Google Scholar
• Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115(19):2490-6
   PubMed Web of Science ®Google Scholar
• Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006;295(12):1420-7
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013;127(3):377-85
   PubMed Web of Science ®Google Scholar
• Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2013;94(4):525-32
   PubMed Web of Science ®Google Scholar
• Lewis JP, Yerges-Armstrong LM, Ellero-Simatos S, et al. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin Pharmacol Ther 2013;94(5):570-3
   PubMed Web of Science ®Google Scholar
• Ellero-Simatos S, Lewis JP, Georgiades A, et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol 2014;3:e125
   PubMedGoogle Scholar
• Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28(14):1702-8
   PubMed Web of Science ®Google Scholar
• Fontana P, Nolli S, Reber G, et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4(4):813-19
   PubMed Web of Science ®Google Scholar
• Wurtz M, Kristensen SD, Hvas AM, et al. Pharmacogenetics of the antiplatelet effect of aspirin. Curr Pharm Des 2012;18(33):5294-308
   PubMed Web of Science ®Google Scholar
• Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003;73(1):122-30
   PubMed Web of Science ®Google Scholar
• Lepantalo A, Mikkelsson J, Resendiz JC, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006;95(2):253-9
   PubMed Web of Science ®Google Scholar
• Li Q, Chen BL, Ozdemir V, et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007;8(6):577-86
   PubMed Web of Science ®Google Scholar
• Clappers N, van Oijen MG, Sundaresan S, et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008;100(1):70-5
   PubMed Web of Science ®Google Scholar
• Pettinella C, Romano M, Stuppia L, et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009;101(4):687-90
   PubMed Web of Science ®Google Scholar
• Kunicki TJ, Williams SA, Nugent DJ, et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009;101(1):123-33
   PubMed Web of Science ®Google Scholar
• Chakroun T, Addad F, Yacoub S, et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. Genet Test Mol Biomarkers 2011;15(7-8):513-16
   PubMed Web of Science ®Google Scholar
• Voora D, Horton J, Shah SH, et al. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am Heart J 2011;162(1):166-72; e1
   PubMed Web of Science ®Google Scholar
• Yi X, Zhou Q, Lin J, et al. Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. J Atheroscler Thromb 2013;20(1):65-72
   PubMed Web of Science ®Google Scholar
• Postula M, Janicki PK, Rosiak M, et al. Effect of common single nucleotide polymorphisms in COX-1 gene on related metabolic activity in diabetic patients treated with acetylsalicylic acid. Arch Med Sci 2014;10(6):1198-205
   Web of Science ®Google Scholar
• Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008;66(2):222-32
   PubMed Web of Science ®Google Scholar
• Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011;306(16):1765-74
   PubMed Web of Science ®Google Scholar
• Carlsson LE, Santoso S, Spitzer C, et al. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999;93(11):3583-6
   PubMed Web of Science ®Google Scholar
• Santoso S, Kunicki TJ, Kroll H, et al. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999;93(8):2449-53
   PubMed Web of Science ®Google Scholar
• Roest M, Banga JD, Grobbee DE, et al. Homozygosity for 807 T polymorphism in alpha(2) subunit of platelet alpha(2)beta(1) is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000;102(14):1645-50
   PubMed Web of Science ®Google Scholar
• Lim E, Carballo S, Cornelissen J, et al. Dose-related efficacy of aspirin after coronary surgery in patients With Pl(A2) polymorphism (NCT00262275). Ann Thorac Surg 2007;83(1):134-8
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003;42(6):1115-19
   PubMed Web of Science ®Google Scholar
• Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005;36(2):276-80
   PubMed Web of Science ®Google Scholar
• Bernardo E, Angiolillo DJ, Ramirez C, et al. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006;17(8):586-90
   PubMed Web of Science ®Google Scholar
• Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, et al. Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood 1999;94(1):186-91
   PubMed Web of Science ®Google Scholar
• Douglas H, Michaelides K, Gorog DA, et al. Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart 2002;87(1):70-4
   PubMed Web of Science ®Google Scholar
• Douglas H, Davies GJ, Michaelides K, et al. Detection of functional differences between different platelet membrane glycoprotein Ibalpha variable number tandem repeat and Kozak genotypes as shown by the PFA-100 system. Heart 2006;92(5):676-8
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Ikeda M, Esumi K, et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J 2007;7(6):395-403
   PubMed Web of Science ®Google Scholar
• Croft SA, Hampton KK, Daly ME, et al. Kozak sequence polymorphism in the platelet GPIbalpha gene is not associated with risk of myocardial infarction. Blood 2000;95(6):2183-4
   PubMed Web of Science ®Google Scholar
• Kauskot A, Di Michele M, Loyen S, et al. A novel mechanism of sustained platelet alphaIIbbeta3 activation via PEAR1. Blood 2012;119(17):4056-65
   PubMed Web of Science ®Google Scholar
• Kauskot A, Vandenbriele C, Louwette S, et al. PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood 2013;121(26):5208-17
   PubMed Web of Science ®Google Scholar
• Jones CI, Bray S, Garner SF, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009;114(7):1405-16
   PubMed Web of Science ®Google Scholar
• Johnson AD, Yanek LR, Chen MH, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 2010;42(7):608-13
   PubMed Web of Science ®Google Scholar
• Herrera-Galeano JE, Becker DM, Wilson AF, et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol 2008;28(8):1484-90
   PubMed Web of Science ®Google Scholar
• Faraday N, Yanek LR, Yang XP, et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 2011;118(12):3367-75
   PubMed Web of Science ®Google Scholar
• Lewis JP, Ryan K, O’Connell JR, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet 2013;6(2):184-92
   PubMed Web of Science ®Google Scholar
• Kim Y, Suktitipat B, Yanek LR, et al. Targeted deep resequencing identifies coding variants in the PEAR1 gene that play a role in platelet aggregation. PLoS One 2013;8(5):e64179
   PubMed Web of Science ®Google Scholar
• Xiang Q, Cui Y, Zhao X, et al. Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics 2013;14(10):1179-89
   PubMed Web of Science ®Google Scholar
• Wurtz M, Lordkipanidze M, Grove EL. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost 2013;11(9):1627-39
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics 2010;20(7):463-5
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38(1):92-9
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294(10):1224-32
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JTIII, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107(23):2908-13
   PubMed Web of Science ®Google Scholar
• Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Int Med 2002;252(3):233-8
   PubMed Web of Science ®Google Scholar
• Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89(5):783-7
   PubMed Web of Science ®Google Scholar
• Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108(7):2244-7
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302(8):849-57
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Shuldiner AR, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 2012;22(2):159-65
   PubMed Web of Science ®Google Scholar
• Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010;4(4):278-81
   PubMedGoogle Scholar
• Martis S, Peter I, Hulot JS, et al. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 2013;13(4):369-77
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94(3):317-23
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Hokimoto S, Chitose T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011;57(2):194-201
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5(12):2429-36
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84(2):236-42
   PubMed Web of Science ®Google Scholar
• Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008;6(8):1439-41
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62
   PubMed Web of Science ®Google Scholar
• Simon T, Bhatt DL, Bergougnan L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 2011;90(2):287-95
   PubMed Web of Science ®Google Scholar
• Gong IY, Crown N, Suen CM, et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J 2012;33(22):2856-64
   PubMed Web of Science ®Google Scholar
• Kelly RP, Close SL, Farid NA, et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol 2012;73(1):93-105
   PubMed Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009;30(14):1744-52
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011;4(4):392-402
   PubMed Web of Science ®Google Scholar
• Fontana P, Hulot JS, De Moerloose P, et al. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007;5(10):2153-5
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-17
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101(8):1088-93
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17(12):1057-64
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Shuldiner AR, Bliden KP, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011;161(3):598-604
   PubMed Web of Science ®Google Scholar
• Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012;59(22):1928-37
   PubMed Web of Science ®Google Scholar
• Hokimoto S, Mizobe M, Akasaka T, et al. Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation. Thromb Res 2014;133(4):599-605
   PubMed Web of Science ®Google Scholar
• Tabata N, Hokimoto S, Akasaka T, et al. Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thromb Res 2014;134(5):939-44
   PubMed Web of Science ®Google Scholar
• Jeong YH, Abadilla KA, Tantry US, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. J Thromb Haemost 2013;11(6):1194-7
   PubMed Web of Science ®Google Scholar
• Jeong YH, Tantry US, Kim IS, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011;4(6):585-94
   PubMed Web of Science ®Google Scholar
• Kim HS, Chang K, Koh YS, et al. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. Circ Cardiovasc Genet 2013;6(5):514-21
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014;7(6):895-902
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009;7(8):1409-11
   PubMed Web of Science ®Google Scholar
• Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010;8(8):1685-93
   PubMed Web of Science ®Google Scholar
• Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160(3):506-12
   PubMed Web of Science ®Google Scholar
• Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6(1):54-61
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-75
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Polasek TM, Wiese MD. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb Haemost 2012;108(1):199-200
   PubMed Web of Science ®Google Scholar
• Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost 2013;11(9):1640-6
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51(20):1925-34
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103(6):806-11
   PubMed Web of Science ®Google Scholar
• Harmsze A, van Werkum JW, Bouman HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 2010;20(1):18-25
   PubMed Web of Science ®Google Scholar
• Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30(8):916-22
   PubMed Web of Science ®Google Scholar
• Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363(18):1704-14
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376(9749):1320-8
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Montalescot G. Genetic substudy of the PLATO trial. Lancet 2011;377(9766):637; author reply 37-8
   PubMed Web of Science ®Google Scholar
• Johnson JA, Roden DM, Lesko LJ, et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012;91(5):774-6
   PubMed Web of Science ®Google Scholar
• Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306(24):2704-14
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304(16):1821-30
   PubMed Web of Science ®Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56(2):134-43
   PubMed Web of Science ®Google Scholar
• Jang JS, Cho KI, Jin HY, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110(4):502-8
   PubMed Web of Science ®Google Scholar
• Jin B, Ni HC, Shen W, et al. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 2011;38(3):1697-702
   PubMed Web of Science ®Google Scholar
• Singh M, Shah T, Adigopula S, et al. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful? Indian Heart J 2012;64(4):341-52
   PubMedGoogle Scholar
• Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11(3):199-206
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Abe T, Sato Y, et al. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. Platelets 2013;24(5):352-61
   PubMed Web of Science ®Google Scholar
• Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012;98(2):100-8
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012;379(9827):1705-11
   PubMed Web of Science ®Google Scholar
• So DY, Wells GA, McPherson R, et al. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J 2015; Epub ahead of print
   PubMedGoogle Scholar
• Ahn SG, Yoon J, Kim J, et al. Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting. Korean Circ J 2013;43(8):541-9
   PubMedGoogle Scholar
• Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol 2013;168(4):3736-40
   PubMed Web of Science ®Google Scholar
• Chevalier B. GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty. In: Foundation CR, editor. Twenty-fifth annual transcatheter cardiovascular therapeutics symposium. Journal of the American College of Cardiology; Moscone Center, San Francisco, California: 2013
   Google Scholar
• Holmes DRJr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56(4):321-41
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(23):e179-347
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 2011;89(5):662-73
   PubMed Web of Science ®Google Scholar
• Jia DM, Chen ZB, Zhang MJ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 2013;44(6):1717-19
   PubMed Web of Science ®Google Scholar
• Sun W, Li Y, Li J, et al. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets 2014;1-5
   PubMed Web of Science ®Google Scholar
• McDonough CW, McClure LA, Mitchell BD, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc 2015;4:6
   Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57(25):2474-83
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376(9749):1312-19
   PubMed Web of Science ®Google Scholar
• Simon T, Steg PG, Becquemont L, et al. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 2011;90(4):561-7
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Knight S, Horne BD, et al. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost 2013;109:4
   PubMed Web of Science ®Google Scholar
• Verschuren JJ, Boden H, Wessels JA, et al. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Int J Cardiol 2013;167(6):2882-8
   PubMed Web of Science ®Google Scholar
• Su J, Xu J, Li X, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One 2012;7(10):e46366
   PubMed Web of Science ®Google Scholar
• Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 2013;23(1):1-8
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang X, Gawronski BE, et al. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 2013;344(3):665-72
   PubMed Web of Science ®Google Scholar
• Park KW, Park JJ, Jeon KH, et al. Enhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011;31(3):665-71
   PubMed Web of Science ®Google Scholar
• Cresci S, Depta JP, Lenzini PA, et al. Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet 2014;7(3):277-86
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010;31(24):3046-53
   PubMed Web of Science ®Google Scholar
• Gremmel T, Kopp CW, Seidinger D, et al. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int J Cardiol 2013;166(1):126-31
   PubMed Web of Science ®Google Scholar
• Gladding P, White H, Voss J, et al. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. JACC Cardiovasc Interv 2009;2(11):1095-101
   PubMed Web of Science ®Google Scholar
• Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109(2):166-71
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26(8):1895-900
   PubMed Web of Science ®Google Scholar
• Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174(12):1715-22
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 2008;64(6):589-97
   PubMed Web of Science ®Google Scholar
• Wu H, Qian J, Xu J, et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics 2012;22(12):887-90
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Owens J, Jin Y, et al. Cytochrome P450 3A4*22, PPAR-alpha, and ARNT polymorphisms and clopidogrel response. Clin Pharmacol 2013;5:185-92
   PubMedGoogle Scholar
• Park JJ, Park KW, Kang J, et al. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. Int J Cardiol 2013;163(1):79-86
   PubMed Web of Science ®Google Scholar
• Viviani Anselmi C, Briguori C, Roncarati R, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 2013;6(11):1166-75
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108(8):989-95
   PubMed Web of Science ®Google Scholar
• von Beckerath N, von Beckerath O, Koch W, et al. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005;16(3):199-204
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116(6):491-7
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007;119(3):355-60
   PubMed Web of Science ®Google Scholar
• Smith SM, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006;17(4):250-8
   PubMed Web of Science ®Google Scholar
• Namazi S, Kojuri J, Khalili A, et al. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochem Pharmacol 2012;83(7):903-8
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17(1):110-16
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Cayla G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011;4(5):422-8
   PubMed Web of Science ®Google Scholar
• Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 2011;90(4):568-74
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011;32(13):1605-13
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W, Fromm MF, et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011;4(4):429-36
   PubMed Web of Science ®Google Scholar
• Ancrenaz V, Desmeules J, James R, et al. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol 2012;166(8):2362-70
   PubMed Web of Science ®Google Scholar
• Reny JL, Combescure C, Daali Y, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2012;10(7):1242-51
   PubMed Web of Science ®Google Scholar
• Reny JL, Combescure C, Daali Y, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2012;10(7):1242-51
   PubMed Web of Science ®Google Scholar
• Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34(4):600-7
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153(1):66; e9-16
   PubMed Web of Science ®Google Scholar
• Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50(5):555-62
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29(1):21-30
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119(19):2553-60
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116(25):2923-32
   PubMed Web of Science ®Google Scholar
• Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58(5):467-73
   PubMed Web of Science ®Google Scholar
• Cuisset T, Loosveld M, Morange PE, et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 2012;5(12):1280-7
   PubMed Web of Science ®Google Scholar
• Grosdidier C, Quilici J, Loosveld M, et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 2013;111(7):985-90
   PubMed Web of Science ®Google Scholar
• Htun WW, Steinhubl SR. Ticagrelor: the first novel reversible P2Y(12) inhibitor. Expert Opin Pharmacother 2013;14(2):237-45
   PubMed Web of Science ®Google Scholar
• Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 2012;51(5):305-18
   PubMed Web of Science ®Google Scholar
• Dinicolantonio JJ, Serebruany VL. Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology 2013;124(2):105-7
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120(25):2577-85
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Varenhorst C EN, Johansson A, Barratt B, et al. Ticagrelor plasma levels but not clinical outcomes are associated with transporter and metabolism enzyme genetic polymorphisms. J Am Coll Cardiol 2014;63:12 S
   Web of Science ®Google Scholar
• Sharfstein J. FDA Regulation of laboratory-developed diagnostic tests: protect the public, advance the science. JAMA 2015;313(7):667-8
   PubMed Web of Science ®Google Scholar
• Evans JP, Watson MS. Genetic testing and fda regulation: overregulation threatens the emergence of genomic medicine. JAMA 2015;313(7):669-70
   PubMed Web of Science ®Google Scholar
• Rubinstein WS, Maglott DR, Lee JM, et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res 2013;41(Database issue):D925-35
   PubMed Web of Science ®Google Scholar
• Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011;13(12):987-95
   PubMed Web of Science ®Google Scholar
• Abul-Husn NS, Owusu Obeng A, Sanderson SC, et al. Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics Pers Med 2014;7:227-40
   PubMedGoogle Scholar
• Johnson JA, Elsey AR, Clare-Salzler MJ, et al. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 2013;14(7):723-6
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet 2014;166C(1):76-84
   PubMed Web of Science ®Google Scholar
• Haga SB, Moaddeb J. Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics 2014;24(3):139-45
   PubMed Web of Science ®Google Scholar
• Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther 2013;94(2):214-17
   PubMed Web of Science ®Google Scholar
• Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012;92(1):87-95
   PubMed Web of Science ®Google Scholar
• Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther 2014;96(4):482-9
   PubMed Web of Science ®Google Scholar
• Hulot JS, Fuster V. Antiplatelet therapy: Personalized medicine for clopidogrel resistance? Nat Rev Cardiol 2009;6(5):334-6
   PubMed Web of Science ®Google Scholar
• Fontana P, Cattaneo M, Combescure C, et al. Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc 2013;2(2):e000131
   PubMed Web of Science ®Google Scholar
• Burke W, Emery J. Genetics education for primary-care providers. Nat Rev Genet 2002;3(7):561-6
   PubMed Web of Science ®Google Scholar
• Murray MF. Educating physicians in the era of genomic medicine. Genome Med 2014;6(6):45
   PubMedGoogle Scholar
• Nickola TJ, Green JS, Harralson AF, et al. The current and future state of pharmacogenomics medical education in the USA. Pharmacogenomics 2012;13(12):1419-25
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 2014;166C(1):56-67
   PubMed Web of Science ®Google Scholar
• Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med 2014;160(4):221-32
   PubMed Web of Science ®Google Scholar
• Reese ES, Daniel Mullins C, Beitelshees AL, et al. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012;32(4):323-32
   PubMed Web of Science ®Google Scholar
• Lala A, Berger JS, Sharma G, et al. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost 2013;11(1):81-91
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Horowitz JD, Sorich W, et al. Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmacogenomics 2013;14(16):2013-21
   PubMed Web of Science ®Google Scholar
• Voora D, Ortel TL, Lucas JE, et al. Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis 2012;33(3):246-57
   PubMed Web of Science ®Google Scholar
• Voora D, Cyr D, Lucas J, et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol 2013;62(14):1267-76
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration In Vitro Diagnostics. Available from: http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm? [Last accessed 30 June 2015]
   Google Scholar
• Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014;11(10):597-606
   PubMed Web of Science ®Google Scholar